Proteostasis Therapeutics Inc. (PTI)

0.67
0.01 1.09
NASDAQ : Health Technology
Prev Close 0.66
Open 0.66
Day Low/High 0.64 / 0.68
52 Wk Low/High 0.61 / 10.38
Volume 178.29K
Avg Volume 946.80K
Exchange NASDAQ
Shares Outstanding 51.10M
Market Cap 32.19M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Proteostasis Therapeutics Announces Management Changes And Appointments

Proteostasis Therapeutics Announces Management Changes And Appointments

Geoffrey S. Gilmartin, MD, MMSc, to Succeed Po-Shun Lee, MD as Chief Medical Officer; Dr. Lee to Remain a Consultant for the Company

Proteostasis Therapeutics Receives Orphan Drug Designation In The EU For PTI-428 For The Treatment Of Cystic Fibrosis

Proteostasis Therapeutics Receives Orphan Drug Designation In The EU For PTI-428 For The Treatment Of Cystic Fibrosis

BOSTON, June 4, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by...

Proteostasis Therapeutics Announces Presentations And Hosts Educational Symposium At The 42nd European Cystic Fibrosis Conference

Proteostasis Therapeutics Announces Presentations And Hosts Educational Symposium At The 42nd European Cystic Fibrosis Conference

BOSTON, June 3, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused...

Proteostasis Therapeutics To Present At The 2019 RBC Capital Markets Global Healthcare Conference

Proteostasis Therapeutics To Present At The 2019 RBC Capital Markets Global Healthcare Conference

BOSTON, May 15, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused...

Proteostasis Therapeutics Appoints Dr. Badrul Chowdhury, Former FDA Director Of Pulmonology, Allergy, And Rheumatology, To Board Of Directors

Proteostasis Therapeutics Appoints Dr. Badrul Chowdhury, Former FDA Director Of Pulmonology, Allergy, And Rheumatology, To Board Of Directors

BOSTON, May 13, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by...

Proteostasis Therapeutics Reports First Quarter 2019 Financial Results And Provides Corporate Update

Proteostasis Therapeutics Reports First Quarter 2019 Financial Results And Provides Corporate Update

BOSTON, May 8, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by...

Proteostasis Therapeutics Announces Broad New Dataset From Proprietary Combination And Add-On CFTR Modulator Studies In Cystic Fibrosis Patients

Proteostasis Therapeutics Announces Broad New Dataset From Proprietary Combination And Add-On CFTR Modulator Studies In Cystic Fibrosis Patients

Greatest ppFEV1 Improvement Shown in High Dose Triplet with Mean Absolute Improvement in ppFEV1 of 8 Percentage Points at 14 Days Compared to Placebo (p<0.05) in Subjects with Two F508del Mutations (F/F) Not Predisposed to Rapid Pulmonary Decline

First Week Of PTI May 17th Options Trading

First Week Of PTI May 17th Options Trading

Investors in Proteostasis Therapeutics Inc saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTI options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Proteostasis Therapeutics Appoints David Arkowitz To Board Of Directors

Proteostasis Therapeutics Appoints David Arkowitz To Board Of Directors

BOSTON, March 7, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused...

Proteostasis Selected To Join European Consortium To Pioneer Personalized Medicine In Cystic Fibrosis

Proteostasis Selected To Join European Consortium To Pioneer Personalized Medicine In Cystic Fibrosis

PTI-428, PTI-801 and PTI-808 Testing Underway in Organoids from CF Patients, with Potential for Clinical Data in 2020

Noteworthy Friday Option Activity: PTI, PZZA, LMNX

Noteworthy Friday Option Activity: PTI, PZZA, LMNX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Proteostasis Therapeutics Inc , where a total volume of 3,679 contracts has been traded thus far today, a contract volume which is representative of approximately 367,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 49.7% of PTI's average daily trading volume over the past month, of 739,780 shares.

First Week Of December 21st Options Trading For Proteostasis Therapeutics (PTI)

First Week Of December 21st Options Trading For Proteostasis Therapeutics (PTI)

Investors in Proteostasis Therapeutics Inc saw new options become available this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTI options chain for the new December 21st contracts and identified one put and one call contract of particular interest.

Noteworthy Thursday Option Activity: PTI, ECYT, PTE

Noteworthy Thursday Option Activity: PTI, ECYT, PTE

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Proteostasis Therapeutics Inc , where a total of 30,198 contracts have traded so far, representing approximately 3.0 million underlying shares. That amounts to about 1693.8% of PTI's average daily trading volume over the past month of 178,285 shares.

First Week Of PTI August 17th Options Trading

First Week Of PTI August 17th Options Trading

Investors in Proteostasis Therapeutics Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTI options chain for the new August 17th contracts and identified the following put contract of particular interest.

First Week Of PTI May 18th Options Trading

Investors in Proteostasis Therapeutics Inc saw new options begin trading this week, for the May 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTI options chain for the new May 18th contracts and identified the following put contract of particular interest.

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Proteostasis Therapeutics, Inc. Investors (PTI)

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Proteostasis Therapeutics, Inc. Investors (PTI)

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation For PTI-428 In Cystic Fibrosis

Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation For PTI-428 In Cystic Fibrosis

Designation granted for PTI-428 for the treatment of CF patients based on the results from a recent Phase 2, randomized, placebo controlled study

That Wild Market Momentum Has Cooled

That Wild Market Momentum Has Cooled

But here are some movers I am looking at today.

TheStreet Quant Rating: D (Sell)